Merck 2Q profit more than doubles

Jul 29, 2014 by Linda A. Johnson

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.

The maker of popular Type 2 diabetes pill Januvia and cholesterol medicines Vytorin and Zetia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Merck, based in Whitehouse Station, New Jersey, said its earnings, adjusted for one-time gains and costs, were 85 cents per share. The average per-share estimate of analysts surveyed by Zacks Investment Research was for profit of 81 cents.

Merck recorded a gain of $741 million from AstraZeneca PLC, its longtime partner in marketing the British drugmaker's heartburn drugs Nexium and Prilosec. AstraZeneca exercised its option to buy out Merck's interest in the drugs.

The world's fourth-biggest drugmaker reported revenue of $10.93 billion, down 1 percent from $11.01 billion a year ago. That edged past Wall Street expectations of $10.71 billion, according to Zacks.

Sales of Merck's prescription drugs totaled $9.09 billion, down 2 percent as cheaper generic competition cut into sales of some older medicines and sales of its hepatitis C drugs was hurt by new brand-name competition. Sales were led by Type 2 diabetes pills Januvia and Janumet, up 2 percent at $1.58 billion, and Zetia and Vytorin, up 6 percent to a combined $1.13 billion.

Sales of veterinary medicines edged up 2 percent to $872 million. Merck's smallest segment, consumer health products, had the best performance, up 19 percent to $583 million. In May, Merck agreed to sell that to Germany's Bayer for $14.2 billion. It includes Claritin, the Coppertone sun-care line, Dr. Scholl's foot-care products and MiraLAX laxative.

Merck has said it would use the money to invest in business areas with the highest growth potential and beef up its drug pipeline with "external assets." The deal is expected to close in the second half of 2014.

Merck said it expects profit for 2014 of $3.43 to $3.53 per share, excluding one-time items. In January, it forecast earnings of $3.35 to $3.53. It also forecast full-year sales $42.4 billion to $43.2 billion, assuming current exchange rates.

"We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs," CEO Kenneth Frazier said in a statement.

In premarket trading, Merck shares were down 18 cents at $57.97. Merck shares have increased $9.63, or 20 percent, in the last 12 months.

Explore further: Merck 1Q profit up 7 pct. despite sales decline

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck 1Q profit up 7 pct. despite sales decline

Apr 29, 2014

Major cost cuts enabled drugmaker Merck & Co. to offset lower first-quarter sales as generic competition continues to hurt sales of former blockbuster medicines. Merck's profit rose 7 percent, trouncing Wall Street expectations.

Generic competition cuts Merck's Q1 sales, profit

May 01, 2013

Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Merck Q4 net drops 14 pct. on generic competition

Feb 05, 2014

Merck & Co. reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.

Merck 3Q net income falls on charges, lower sales

Oct 28, 2013

Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...

Merck's 2Q net falls on charges, but sales rise

Jul 27, 2012

Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares ...

Recommended for you

Out-of-patience investors sell off Amazon

3 hours ago

Amazon has long acted like an ideal customer on its own website: a freewheeling big spender with no worries about balancing a checkbook. Investors confident in founder and CEO Jeff Bezos' invest-and-expand ...

States ascend into the cloud

9 hours ago

Seven years ago, the state of Delaware started moving computer servers out of closets and from under workers' desks to create a consolidated data center and a virtual computing climate.

Microsoft drops Nokia name from smartphones

11 hours ago

Microsoft said Friday it was dropping the Nokia name from its Lumia smartphones, rebranding following the acquisition earlier this year of the Finnish group's handset division.

Amazon's loss makes holidays a question mark

12 hours ago

Amazon's trademark smile icon is becoming more of a grimace. The world's largest online retailer reported a wider third-quarter loss than analysts expected and gave a disappointing holiday forecast.

User comments : 0